Mazen Roumia, MD
Interventional Cardiology · Scottsdale, AZNPI 1649405812
Payments from drug & device makers
Across 280 payments — averaging $85.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$13K
- Abbott$3K
- Edwards Lifesciences$3K
- Boston Scientific$992
- E.r. Squibb & Sons, L.L.C.$625
- Novartis$597
- plus $3K from 22 others
What the payments were for
- Travel & lodging$16,46369%
- Food & beverage$7,40231%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 26 | $13,094 |
| Abbott | 21 | $2,895 |
| Edwards Lifesciences | 18 | $2,514 |
| Boston Scientific | 8 | $992 |
| E.r. Squibb & Sons, L.L.C. | 32 | $625 |
| Novartis | 31 | $597 |
| Pfizer | 29 | $547 |
| AstraZeneca | 21 | $409 |
| Amgen | 22 | $383 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $343 |
| Shockwave Medical, Inc | 4 | $258 |
| Actelion Pharmaceuticals US, Inc. | 6 | $252 |
| Johnson & Johnson | 9 | $224 |
| Boehringer Ingelheim | 11 | $197 |
| Sanofi-aventis U.S. LLC | 4 | $76 |
| Vifor Pharma, Inc. | 3 | $68 |
| Amarin Pharma, Inc. | 3 | $58 |
| Abiomed | 2 | $56 |
| Bridgebio Pharma, Inc. | 1 | $50 |
| Lantheus Medical Imaging, Inc. | 2 | $46 |
| Z-medica, LLC | 2 | $44 |
| Philips North America LLC | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Cvrx, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$12,377
- Mitra Clip system$1,661
- EVOQUE$1,038
- PASCAL$830
- Watchman$791
- TRICLIP$740
- SAPIEN 3 Ultra RESILIA$213
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$210
- UPTRAVI$121
- OPSUMIT$121
- RESOLUTE ONYX$118
- WATCHMAN Access System$114
How this compares
$23,864 in reported general payments places this provider in the 65th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 217 | $239,855 |
| EntrestoSacubitril/Valsartan | 69 | $74,661 |
| JardianceEmpagliflozin | 39 | $42,427 |
| XareltoRivaroxaban | 45 | $41,016 |
| Droxidopa | 13 | $32,612 |
| VascepaIcosapent Ethyl | 29 | $13,467 |
| Repatha SureclickEvolocumab | 22 | $12,763 |
| Metoprolol Succinate | 350 | $6,952 |
| Atorvastatin Calcium | 308 | $4,391 |
| Rosuvastatin Calcium | 52 | $2,197 |
| Losartan Potassium | 185 | $2,033 |
| Amlodipine Besylate | 241 | $1,902 |
| ClopidogrelClopidogrel Bisulfate | 93 | $1,483 |
| Ranolazine ErRanolazine | 13 | $1,434 |
| Lisinopril | 176 | $1,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $547 | $239,855217 claims |
| NovartisEntresto | $597 | $74,66169 claims |
| Boehringer IngelheimJardiance | $197 | $42,42739 claims |
| Johnson & JohnsonXarelto | $224 | $41,01645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Scottsdale
- Taral PatelScottsdale$377K
- Andrew CluckeyScottsdale$116K
- Rebecca ChesterScottsdale$113K
- Mayurkumar BhaktaScottsdale$82K
- Nassim HaddadScottsdale$53K
- Kwan LeeScottsdale$53K
- Paul SorajjaPhoenix$8.8M
- Thomas WaggonerTucson$4.1M
- Hursh NaikAvondale$2.2M
- Nabil DibGilbert$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.